Kerendia

(Finerenone)

ApprovedSmall molecule

Finerenone is used to treat kidney disease in patients with type 2 diabetes and to reduce the risk of heart and kidney problems in these patients.[2] Kerendia is currently approved and in use across 24 indications[4].[1]

Kerendia is one of 489 small molecule programs targeting Albuminuria. It is currently in Approved.

Indications

Total Trials

Active Trials

488

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

AlbuminuriaNot yet recruiting

GlomerulonephritisRecruiting

IGA GlomerulonephritisApproved

Diabetic NephropathyApproved

Type 2 Diabetes MellitusCompleted

Primary AldosteronismCompleted

Kidney DiseaseEnrolling by invitation

Kidney TransplantRecruiting

Oxidative StressRecruiting

Diabetes MellitusApproved

AlbuminuriaApproved

Not yet recruiting

GlomerulonephritisPhase 2

Recruiting

IGA GlomerulonephritisApproved

Approved

Diabetic NephropathyApproved

Approved

Type 2 Diabetes MellitusApproved

Completed

Primary AldosteronismApproved

Completed

Kidney DiseaseApproved

Enrolling by invitation

Kidney TransplantPhase 2

Recruiting

Oxidative StressPhase 3

Recruiting

Diabetes MellitusApproved

Approved

Showing 10 of 24 indications

Competition

Competitive Landscape

198 competitors in Heart Failure

#DrugCompanyPhaseTrials

Kerendia

Bayer

Approved

7 2

Brethine

Sanofi

Preclinical

1 3

Medrol

Pfizer

Preclinical

1 4

Amidate

Pfizer

Preclinical

1 5

Activase

Zemplar

Adriamycin

Savaysa

Xifaxan

2 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Chronic Kidney Disease

NCT06838416

Post-ApprovalRecruiting

Chronic Kidney Disease

NCT06727409

Q1 2027

PreclinicalNot yet recruiting

Albuminuria

NCT07849348

Post-ApprovalNot yet recruiting

Chronic Kidney Disease

NCT07235891

Q2 2027

Phase 3Active, not recruiting

Chronic Kidney Disease

NCT05196035

Q3 2027

ApprovedNot yet recruiting

Diabetic Kidney Disease

NCT07155694

Clinical

Trials by Indication[1]

Chronic Kidney Disease16 trials

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

Completed· Bayer logo

Bayer·Phase 3·NCT05047263·1,584 enrolled

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

Completed· Bayer logo

Bayer··NCT05526157·50,000 enrolled

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

Completed· Bayer logo

Bayer··NCT05640180·17,847 enrolled

Show 13 more trials

FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors

Not yet recruiting·UUniversity Medical Center Groningen·Phase 3·NCT07181135·180 enrolled

Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease

Not yet recruiting·—·Phase 4·NCT07235891·40 enrolled

Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease

Recruiting·SSecond Affiliated Hospital of Soochow University··NCT06838416·300 enrolled

Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease

Recruiting·—·Phase 4·NCT06727409·82 enrolled

A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

Recruiting·PPeter Rossing·Phase 4·NCT07239570·125 enrolled

A Parallel-group, Randomized, Prospective, Interventional, Double-blind, Multicenter Global Phase 3 Study to Investigate the Efficacy and Safety of Finerenone Versus Placebo, in Addition to Standard of Care, in Participants With Chronic Kidney Disease and Type 1 Diabetes

Completed· Bayer logo

Bayer·Phase 3·NCT05901831·242 enrolled

FIRST-2.5: Finerenone Research of Early Safety and Effectiveness, Part 2.5

Completed· Bayer logo

Bayer··NCT06608212·238,038 enrolled

A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and Proteinuria

Active, not recruiting· Bayer logo

Bayer·Phase 3·NCT05196035·219 enrolled

An Observational Prospective Study to Analyse Changes in the Klinrisk Chronic Kidney Disease Progression Model Score in a Cohort of Patients With CKD Associated With Type 2 Diabetes Treated With Finerenone in Spain

Recruiting· Bayer logo

Bayer··NCT07554469·500 enrolled

Real-world Experience With Finerenone Treatment in Patients From India With Chronic Kidney Disease and Type 2 Diabetes-Retrospective Data Analysis

Active, not recruiting· Bayer logo

Bayer··NCT06763146·1,200 enrolled

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

Enrolling by invitation·BBaylor Research Institute·Approved·NCT07547878·64 enrolled

Optimization of Albuminuria Lowering Therapies to Individual Patients With CKD Using FINErenone and SEmaglutide

Completed·UUniversity Medical Center Groningen·Phase 2·NCT07819227·41 enrolled

An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

Recruiting· Bayer logo

Bayer·Phase 3·NCT05457283·100 enrolled

Type 2 Diabetes Mellitus8 trials

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Completed· Bayer logo

Bayer·Phase 3·NCT02540993·5,734 enrolled

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

Completed· Bayer logo

Bayer·Phase 2·NCT01807221·1,066 enrolled

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Completed· Bayer logo

Bayer·Phase 3·NCT02545049·7,352 enrolled

Show 5 more trials

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

Completed· Bayer logo

Bayer·Phase 2·NCT01874431·823 enrolled

A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients

Recruiting· Bayer logo

Bayer··NCT05552339·5,000 enrolled

A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus

Completed· Bayer logo

Bayer·Phase 4·NCT05705271·200 enrolled

Finerenone for the Treatment of Type 2 Diabetes-Related Kidney Disease: Efficacy Observation and Related Factor Analysis

Not yet recruiting·FFirst Affiliated Hospital of Chongqing Medical University··NCT07717697·425 enrolled

A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.

Completed· Bayer logo

Bayer·Phase 2·NCT05254002·1,664 enrolled

Heart Failure7 trials

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

Completed· Bayer logo

Bayer·Phase 3·NCT04435626·6,016 enrolled

A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea

Recruiting· Bayer logo

Bayer··NCT07379840·300 enrolled

Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure

Not yet recruiting·—·N/A·NCT07326631·120 enrolled

Show 4 more trials

Impact of Finerenone in Combination With Sodium Glucose Cotransporter-2 Inhibitor in Patients With Heart Failure

Active, not recruiting·MMansoura University·Approved·NCT07351864·60 enrolled

Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)

Recruiting·CColorado Prevention Center·Phase 3·NCT06008197·5,200 enrolled

Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF)

Recruiting·CColorado Prevention Center·Phase 3·NCT06024746·1,500 enrolled

A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)

Recruiting·CColorado Prevention Center·Phase 3·NCT06033950·2,600 enrolled

Primary Aldosteronism6 trials

Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism

Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 4·NCT05814770·96 enrolled

Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism

Completed·—·Phase 4·NCT05924620·60 enrolled

Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT06164379·150 enrolled

Show 3 more trials

The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism

Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 4·NCT06381323·55 enrolled

Finerenone for Patients With Primary Aldosteronism (FAIRY): A Multicenter, Randomized Clinical Trial

Completed·QQifu Li·Approved·NCT06457074·306 enrolled

Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism

Recruiting·BBangladesh Medical University·Preclinical·NCT07688928·104 enrolled

Finerenone5 trials

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

Completed· Bayer logo

Bayer·Phase 1·NCT02957396·16 enrolled

A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

Completed· Bayer logo

Bayer·Phase 1·NCT04881994·27 enrolled

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

Completed· Bayer logo

Bayer·Phase 1·NCT02956109·16 enrolled

Show 2 more trials

A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants

Completed· Bayer logo

Bayer·Phase 1·NCT07116512·60 enrolled

Finerenone and Cardiac Remodeling

Not yet recruiting·SSubodh Verma·Phase 3·NCT07270367·156 enrolled

26 more indications

Type 2 Diabetes4 trials

Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.

Recruiting·UUniversity of Aarhus·Phase 4·NCT07026539·80 enrolled

Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

Enrolling by invitation·SSteno Diabetes Center Copenhagen·Phase 4·NCT06954090·50 enrolled

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Completed·UUniversity Medical Center Groningen·Phase 4·NCT06094920·12 enrolled

Show 1 more trial

Clinical Profile, Treatment Patterns and Evolution of the Urinary Albumin-to-creatinine Ratio in Patients With Type 2 Diabetes and Chronic Kidney Disease Treated With Finerenone at the Primary Care of the IMSS: Observational, Prospective, Multicenter Study

Not yet recruiting· Bayer logo

Bayer··NCT07841015·800 enrolled

Observational Study3 trials

An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.

Active, not recruiting· Bayer logo

Bayer··NCT07124039·5,000 enrolled

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

Recruiting· Bayer logo

Bayer··NCT06278207·50,000 enrolled

An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

Completed· Bayer logo

Bayer··NCT05703880·15,948 enrolled

Biomarkers2 trials

Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)

Active, not recruiting·—·Phase 4·NCT05887817·100 enrolled

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

Completed· Bayer logo

Bayer·Phase 2·NCT05013008·951 enrolled

Diabetic Retinopathy2 trials

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)

Completed· Bayer logo

Bayer··NCT04477707·206 enrolled

Completed· Bayer logo

Bayer·N/A·NCT04795726·70 enrolled

IgA Nephropathy2 trials

Effect of Finerenone in IgA Nephropathy

Not yet recruiting·ZZhejiang University·Phase 3·NCT06580288·120 enrolled

Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy

Completed·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine··NCT06460987·245 enrolled

Left Ventricular Systolic Dysfunction2 trials

A Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)

Recruiting· Bayer logo

Bayer·Phase 3·NCT07192952·117 enrolled

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Investigate the Efficacy, Safety, and PK/ PD of Finerenone, in Addition to Standard-of-care, in Pediatric Patients, 6 Months to < 18 Years of Age With Heart Failure (HF) and Left Ventricular Systolic Dysfunction (LVSD)

Recruiting· Bayer logo

Bayer·Phase 3·NCT07188805·111 enrolled

Albuminuria2 trials

Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria

Not yet recruiting·PPeking University People's Hospital·Preclinical·NCT07849348·266 enrolled

Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Not yet recruiting·FFirst Affiliated Hospital of Zhejiang University·Approved·NCT07667517·148 enrolled

Diabetic Kidney Disease2 trials

Role of Finerenone in African American Veterans With Diabetic Kidney Disease

Not yet recruiting·WWashington D.C. Veterans Affairs Medical Center·Approved·NCT07155694·30 enrolled

QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)

Not yet recruiting·HHuijie Zhang·Approved·NCT07775846·820 enrolled

Kidney Transplant1 trial

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

Recruiting·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT06059664·150 enrolled

Oxidative Stress1 trial

Finerenone and Renal Oxidative Stress

Recruiting·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT06244758·75 enrolled

Function1 trial

A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

Completed· Bayer logo

Bayer·Phase 1·NCT04908436·33 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT

Terminated·JJinling Hospital, China·Phase 2·NCT06818305·10 enrolled

Tics1 trial

Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862

Completed· Bayer logo

Bayer·Phase 1·NCT01473108·67 enrolled

Glomerulonephritis1 trial

Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

Recruiting·—·Phase 2·NCT06835322·100 enrolled

Cardiovascular Disease1 trial

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Recruiting·SSteno Diabetes Center Copenhagen·Phase 3·NCT06082063·2,000 enrolled

Kidney Disease1 trial

Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure

Enrolling by invitation·—·Phase 4·NCT07442448·40 enrolled

Nephropathy1 trial

Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial

Recruiting·—·N/A·NCT07056595·30 enrolled

HFpEF - Heart Failure With Preserved Ejection Fraction1 trial

Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure: A Prospective, Multicenter, Randomized, Placebo-Controlled Trial

Recruiting·SSecond Affiliated Hospital, Zhejiang University, School of Medicine·Phase 3·NCT07575672·2,832 enrolled

Heart Failure and Preserved Ejection Fraction1 trial

Impact of Finerenone on Cardiac Electrical Stability in Patients With Heart Failure With Preserved Ejection Fraction

Not yet recruiting·AAssiut University··NCT07866287·100 enrolled

Chronic Kidney Diseases1 trial

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Recruiting·TThe George Institute·Phase 3·NCT06058585·2,000 enrolled

Heart Failure With Preserved Ejection Fraction1 trial

Impact of Finerenone on Cardiac Remodeling and Heart Failure Progression in Patients With Heart Failure With Preserved Ejection Fraction The FIN-HF-LVS Registry

Not yet recruiting·AAssiut University·Approved·NCT07830940·194 enrolled

Premature ovarian insufficiency1 trial

A Randomized, Double-Blind, Placebo-Controlled Trial of Finerenone in Women With Premature Ovarian Insufficiency

Not yet recruiting·TThe University of Hong Kong-Shenzhen Hospital·Phase 2·NCT07815509·46 enrolled

Atrial Fibrillation (AF)1 trial

Finerenone for Reducing Atrial Fibrillation Recurrence After Pulmonary Vein Isolation: A Randomized Pilot Trial With Mechanistic Assessment of Epicardial Adipose Tissue Remodeling and Brown Adipose Tissue Activation

Recruiting·NNational Cheng-Kung University Hospital·Phase 2·NCT07799519·40 enrolled

Acute Kidney Injury1 trial

Finerenone to Improve Acute Kidney Injury; a Multicenter, Randomized, Placebo-Controlled Study to Investigate the Feasibility of Finerenone in Treating Patients With Acute Kidney Injury (FiPAKI Pilot Trial)

Not yet recruiting·JJean-Maxime Côté·Preclinical·NCT07775482·72 enrolled

Acute Heart Failure1 trial

Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure

Recruiting·JJuntendo University·Approved·NCT07397650·550 enrolled

Type 1 Diabetes1 trial

Accelerating Breakthrough Targeted New Therapies for Cardio-Renal Complications in People With T1D (Precision T1D Platform)

Not yet recruiting·OOregon Health and Science University·Phase 2·NCT07594145·57 enrolled

Regulatory

FDA Approval Timeline[5]

Jul 9, 2021

KERENDIA

NDA NDA215341

Sep 1, 2022

KERENDIA

NDA NDA215341

Jul 11, 2025

KERENDIA

NDA NDA215341

Sources

References

[1]
ClinicalTrials.gov — 79 trial records for Finerenone. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Kerendia drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Finerenone compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Finerenone. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA215341). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Kerendia. U.S. Food & Drug Administration.
[7]
PubMed — 2 publications indexed for Finerenone. U.S. National Library of Medicine.
[8]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Nonsteroidal MRA[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Bayer

Patent Landscape[6]

Patent Cliff

Aug 26, 2033

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8436180Aug 26, 2033

RE49826Jul 29, 2035

Key Publications[7]

Cardiovascular and Renal Outcomes With Finerenone: FIGARO-DKD

N Engl J MedJun 24, 2022DOI: 10.1056/NEJMoa2204245

Finerenone in Chronic Kidney Disease and Type 2 Diabetes: FIDELIO-DKD Updated

N Engl J MedMay 19, 2022DOI: 10.1056/NEJMoa2204233

Kerendia

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Chronic Kidney Disease16 trials

Type 2 Diabetes Mellitus8 trials

Heart Failure7 trials

Primary Aldosteronism6 trials

Finerenone5 trials

Type 2 Diabetes4 trials

Observational Study3 trials

Biomarkers2 trials

Diabetic Retinopathy2 trials

IgA Nephropathy2 trials

Left Ventricular Systolic Dysfunction2 trials

Albuminuria2 trials

Diabetic Kidney Disease2 trials

Kidney Transplant1 trial

Oxidative Stress1 trial

Function1 trial

Efficacy and Safety1 trial

Tics1 trial

Glomerulonephritis1 trial

Cardiovascular Disease1 trial

Kidney Disease1 trial

Nephropathy1 trial

HFpEF - Heart Failure With Preserved Ejection Fraction1 trial

Heart Failure and Preserved Ejection Fraction1 trial

Chronic Kidney Diseases1 trial

Heart Failure With Preserved Ejection Fraction1 trial

Premature ovarian insufficiency1 trial

Atrial Fibrillation (AF)1 trial

Acute Kidney Injury1 trial

Acute Heart Failure1 trial

Type 1 Diabetes1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Key Publications[7]

Related News